TERN
NASDAQTerns Pharmaceuticals Inc.
Website
News25/Ratings12
News · 26 weeks62-36%
2025-10-262026-04-19
Mix3190d
- Other15(48%)
- Insider9(29%)
- SEC Filings5(16%)
- Analyst2(6%)
Latest news
25 items- PRMerck Begins Tender Offer to Acquire Terns Pharmaceuticals, Inc.Merck (NYSE:MRK), known as MSD outside of the United States and Canada, is commencing today, through a subsidiary, a cash tender offer to purchase all outstanding shares of common stock of Terns Pharmaceuticals, Inc. ("Terns") (NASDAQ:TERN). On March 25, 2026, Merck announced that it had entered into a definitive agreement to acquire Terns. Upon the successful closing of the tender offer, stockholders of Terns will receive $53.00 net in cash for each share of Terns common stock validly tendered and not validly withdrawn in the offer, without interest and less any applicable tax withholding. Following the purchase of shares in the tender offer, Terns will become a wholly owned subsidiary o
- SECSEC Form SC 14D9 filed by Terns Pharmaceuticals Inc.SC 14D9 - Terns Pharmaceuticals, Inc. (0001831363) (Subject)
- SECSEC Form SC TO-T filed by Terns Pharmaceuticals Inc.SC TO-T - Terns Pharmaceuticals, Inc. (0001831363) (Subject)
- INSIDERSEC Form 4 filed by Kuriakose Emil4 - Terns Pharmaceuticals, Inc. (0001831363) (Issuer)
- PRTerns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)FOSTER CITY, Calif., April 02, 2026 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage oncology company, today announced that it has granted as of April 1, 2026 equity inducement awards to three new employees under the terms of the 2022 Employment Inducement Award Plan, as amended. The equity awards were approved by the Compensation Committee of the Company's Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4) and were made as a material inducement to the employees' acceptance of employment with Terns. The Company granted 23,316 restricted stock units (the "RSUs"), in the aggregate, of Terns common stock to the new e
- SECSEC Form S-8 filed by Terns Pharmaceuticals Inc.S-8 - Terns Pharmaceuticals, Inc. (0001831363) (Filer)
- SECSEC Form 10-K filed by Terns Pharmaceuticals Inc.10-K - Terns Pharmaceuticals, Inc. (0001831363) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Terns Pharmaceuticals Inc.SCHEDULE 13G/A - Terns Pharmaceuticals, Inc. (0001831363) (Subject)
- SECSEC Form SC TO-C filed by Terns Pharmaceuticals Inc.SC TO-C - Terns Pharmaceuticals, Inc. (0001831363) (Subject)
- SECSEC Form SC14D9C filed by Terns Pharmaceuticals Inc.SC14D9C - Terns Pharmaceuticals, Inc. (0001831363) (Subject)
- SECSEC Form SC TO-C filed by Terns Pharmaceuticals Inc.SC TO-C - Terns Pharmaceuticals, Inc. (0001831363) (Subject)
- ANALYSTTerns Pharmaceuticals downgraded by H.C. WainwrightH.C. Wainwright downgraded Terns Pharmaceuticals from Buy to Neutral
- SECSEC Form SC14D9C filed by Terns Pharmaceuticals Inc.SC14D9C - Terns Pharmaceuticals, Inc. (0001831363) (Subject)
- SECSEC Form SC TO-C filed by Terns Pharmaceuticals Inc.SC TO-C - Terns Pharmaceuticals, Inc. (0001831363) (Subject)
- SECTerns Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Terns Pharmaceuticals, Inc. (0001831363) (Filer)
- PRMerck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML)Terns' lead candidate TERN-701 is an investigational oral allosteric BCR::ABL1 tyrosine kinase inhibitor currently in Phase 1/2 development for certain patients with CML Merck to hold investor call at 8 a.m. EDT today RAHWAY, N.J. and FOSTER CITY, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Merck (NYSE:MRK), known as MSD outside of the United States and Canada, and Terns Pharmaceuticals, Inc. ("Terns") (NASDAQ:TERN), a clinical-stage oncology company, today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Terns for $53.00 per share in cash for an approximate equity value of $6.7 billion. This equates to approximate
- PRMerck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML)Terns' lead candidate TERN-701 is an investigational oral allosteric BCR::ABL1 tyrosine kinase inhibitor currently in Phase 1/2 development for certain patients with CML Merck to hold investor call at 8 a.m. EDT today Merck (NYSE:MRK), known as MSD outside of the United States and Canada, and Terns Pharmaceuticals, Inc. ("Terns") (NASDAQ:TERN), a clinical-stage oncology company, today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Terns for $53.00 per share in cash for an approximate equity value of $6.7 billion. This equates to approximately $5.7 billion net of acquired cash and represents an approximate premi
- INSIDERChief Executive Officer Burroughs Amy L. exercised 14,583 shares at a strike of $4.64 and sold $681,108 worth of shares (14,583 units at $46.71) (SEC Form 4)4 - Terns Pharmaceuticals, Inc. (0001831363) (Issuer)
- PRTerns Pharmaceuticals to Participate in Upcoming March Investor ConferencesFOSTER CITY, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage oncology company, today announced that members of senior management will be participating in the following upcoming investor conferences in March. TD Cowen's 46th Annual Health Care ConferenceFormat: Fireside ChatDate and Time: Monday, March 2, 2026 at 3:50 p.m. ET Location: Boston, MA Leerink Global Healthcare Conference Format: Fireside ChatDate and Time: Monday, March 9, 2026 at 1:40 p.m. ET Location: Miami, FL Barclays 28th Annual Global Healthcare Conference Format: 1x1 MeetingsDate: Tuesday, March 10, 2026Location: Miami, FL The Citizens Li
- INSIDERChief Executive Officer Burroughs Amy L. exercised 14,583 shares at a strike of $4.64 and sold $571,579 worth of shares (14,583 units at $39.19) (SEC Form 4)4 - Terns Pharmaceuticals, Inc. (0001831363) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Terns Pharmaceuticals Inc.SCHEDULE 13G/A - Terns Pharmaceuticals, Inc. (0001831363) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Terns Pharmaceuticals Inc.SCHEDULE 13G/A - Terns Pharmaceuticals, Inc. (0001831363) (Subject)
- SECSEC Form SCHEDULE 13G filed by Terns Pharmaceuticals Inc.SCHEDULE 13G - Terns Pharmaceuticals, Inc. (0001831363) (Subject)
- ANALYSTLeerink Partners initiated coverage on Terns Pharmaceuticals with a new price targetLeerink Partners initiated coverage of Terns Pharmaceuticals with a rating of Outperform and set a new price target of $58.00
- INSIDERSEC Form 4 filed by Director Turner Heather D4 - Terns Pharmaceuticals, Inc. (0001831363) (Issuer)